Skip to main content

Advertisement

SpringerLink
Log in

Myelopathy associated with mixed connective tissue disease: clinical manifestation, diagnosis, treatment, and prognosis

  • Review Article
  • Published:
Neurological Sciences Aims and scope Submit manuscript

Abstract

Mixed connective tissue disease (MCTD) is a chronic autoimmune disease, which has a broad range of clinical manifestations shared by systemic lupus erythematosus, systemic sclerosis, polymyositis/dermatomyositis, and rheumatoid arthritis. MCTD is featured with high serum titers of anti-ribonucleoprotein antibodies and multiple system involvement. Its spinal cord involvement mainly manifests as transverse myelopathy (TM) and longitudinal extensive transverse myelopathy (LETM). Myelopathy in MCTD is extremely rare, and is usually characterized by serious neurological complications, such as paralysis or muscular paresis, sensory impairment, and smooth muscle dysfunction. Progressive clinical manifestations combined with laboratory examinations and magnetic resonance imaging examinations play important roles in the diagnosis of this disease. In order to prevent permanent neurological damage to the spinal cord, plasmapheresis and intravenous immunoglobulin can be performed in patients at the early disease stage. Early high-dose corticosteroids combined with cyclophosphamide, followed by low doses of immunosuppressors, can improve the long-term prognosis of patients. There are only nine global cases reported on MCTD associated with myelopathy at present. The death rate and disability rate of myelopathy in MCTD are extremely high. In this review, the pathomechanisms, clinical manifestations, auxiliary examination, diagnosis, differential diagnosis, treatment, and prognosis of myelopathy in MCTD were systematically elucidated.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1

Similar content being viewed by others

References

  1. Sharp GC, Irvin WS, Tan EM, Gould RG, Holman HR (1972) Mixed connective tissue disease--an apparently distinct rheumatic disease syndrome associated with a specific antibody to an extractable nuclear antigen (ENA). Am J Med 52(2):148–159

    Article  CAS  PubMed  Google Scholar 

  2. Hoffman R, Bezruczko N, Perkins K (2012) An external validation study of a classification of mixed connective tissue disease and systemic lupus erythematosus patients. J Appl Meas 13(2):205–216

  3. Perkins K, Hoffman RW, Bezruczko N (2008) A Rasch analysis for classification of systemic lupus erythematosus and mixed connective tissue disease. J Appl Meas 9(2):136–150

  4. Weiss T, Nelson J, Woolsey R, Zuckner J, Baldassare A (1978) Transverse myelitis in mixed connective tissue disease. Arthritis Rheum 21(8):982–986

    Article  CAS  PubMed  Google Scholar 

  5. Nichtweiß M, Weidauer S (2015) Differential diagnosis of acute myelopathies: an update. Clin Neuroradiol 25(Suppl 2):183–187

    Article  PubMed  Google Scholar 

  6. Minkin W, Rabhan N (1976) Mixed connective tissue disease. Arch Dermatol 112(11):1535–1538

    Article  CAS  PubMed  Google Scholar 

  7. Gunnarsson R, Molberg O, Gilboe IM, Gran JT (2011) The prevalence and incidence of mixed connective tissue disease: a national multicentre survey of Norwegian patients. Ann Rheum Dis 70(6):1047–1051. https://doi.org/10.1136/ard.2010.143792

    Article  PubMed  Google Scholar 

  8. Ungprasert P, Crowson CS, Chowdhary VR, Ernste FC, Moder KG, Matteson EL (2016) Epidemiology of mixed connective tissue disease, 1985–2014: a population-based study. Arthritis Care Res 68(12):1843–1848. https://doi.org/10.1002/acr.22872

    Article  Google Scholar 

  9. Ferucci E, Johnston J, Gordon C, Helmick C, Lim S (2017) Prevalence of mixed connective tissue disease in a population-based Registry of American Indian/Alaska Native People in 2007. Arthritis Care Res 69(8):1271–1275

    Article  Google Scholar 

  10. Paradowska-Gorycka A, Stypinska B, Olesinska M, Felis-Giemza A, Manczak M, Czuszynska Z, Zdrojewski Z, Wojciechowicz J, Jurkowska M (2016) Association of HLA-DRB1 alleles with susceptibility to mixed connective tissue disease in Polish patients. Hla 87(1):13–18. https://doi.org/10.1111/tan.12698

    Article  CAS  PubMed  Google Scholar 

  11. Paradowska-Gorycka A (2015) U1-RNP and Toll-like receptors in the pathogenesis of mixed connective tissue diseasePart II. Endosomal TLRs and their biological significance in the pathogenesis of mixed connective tissue disease. Reumatologia 53(3):143–151

    Article  PubMed  PubMed Central  Google Scholar 

  12. Hameenkorpi R, Ruuska P, Forsberg S, Tiilikainen R, Makitalo R, Hakala M (1993) More evidence of distinctive features of mixed connective tissue disease. Scand J Rheumatol 22(2):63–68

    Article  CAS  PubMed  Google Scholar 

  13. Yoshida K, Inoue H, Komai K, Yamane T, Hashiramoto A, Shiozawa K, Shiozawa S (2013) Mixed connective tissue disease is distinct from systemic lupus erythematosus: study of major histocompatibility complex class I polypeptide-related sequence A and HLA gene polymorphisms. Tissue Antigens 81(1):44–45. https://doi.org/10.1111/tan.12027

    Article  CAS  PubMed  Google Scholar 

  14. Martínez-Barrio J, Valor L, López-Longo F (2018) Facts and controversies in mixed connective tissue disease. Med Clin (Barc) 150(1):26–32

    Article  Google Scholar 

  15. Dima A, Jurcut C, Baicus C (2018) The impact of anti-U1-RNP positivity: systemic lupus erythematosus versus mixed connective tissue disease. Rheumatol Int 38(7):1169–1178. https://doi.org/10.1007/s00296-018-4059-4

    Article  CAS  PubMed  Google Scholar 

  16. Sharp GC, Irvin WS, May CM, Holman HR, McDuffie FC, Hess EV, Schmid FR (1976) Association of antibodies to ribonucleoprotein and Sm antigens with mixed connective-tissue disease, systematic lupus erythematosus and other rheumatic diseases. N Engl J Med 295(21):1149–1154. https://doi.org/10.1056/nejm197611182952101

    Article  CAS  PubMed  Google Scholar 

  17. Minkin W, Rabhan N (1977) Mixed connective tissue disease. Arch Intern Med 137(10):1484

    Article  CAS  PubMed  Google Scholar 

  18. Hoffmann-Vold AM, Gunnarsson R, Garen T, Midtvedt Ø, Molberg Ø (2015) Performance of the 2013 American College of Rheumatology/European League Against Rheumatism Classification Criteria for Systemic Sclerosis (SSc) in large, well-defined cohorts of SSc and mixed connective tissue disease. J Rheumatol 42(1):60–63

    Article  PubMed  Google Scholar 

  19. Doria A, Ghirardello A, de Zambiasi P, Ruffatti A, Gambari PF (1992) Japanese diagnostic criteria for mixed connective tissue disease in Caucasian patients. J Rheumatol 19(2):259–264

    CAS  PubMed  Google Scholar 

  20. Amigues JM, Cantagrel A, Abbal M, Mazieres B (1996) Comparative study of 4 diagnosis criteria sets for mixed connective tissue disease in patients with anti-RNP antibodies. Autoimmunity Group of the Hospitals of Toulouse. J Rheumatol 23(12):2055–2062

    CAS  PubMed  Google Scholar 

  21. Cappelli S, Bellando Randone S, Martinovic D, Tamas MM, Pasalic K, Allanore Y, Mosca M, Talarico R, Opris D, Kiss CG, Tausche AK, Cardarelli S, Riccieri V, Koneva O, Cuomo G, Becker MO, Sulli A, Guiducci S, Radic M, Bombardieri S, Aringer M, Cozzi F, Valesini G, Ananyeva L, Valentini G, Riemekasten G, Cutolo M, Ionescu R, Czirjak L, Damjanov N, Rednic S, Matucci Cerinic M (2012) "To be or not to be," ten years after: evidence for mixed connective tissue disease as a distinct entity. Semin Arthritis Rheum 41(4):589–598. https://doi.org/10.1016/j.semarthrit.2011.07.010

    Article  PubMed  Google Scholar 

  22. Flåm S, Gunnarsson R, Garen T, Lie B, Molberg Ø (2015) The HLA profiles of mixed connective tissue disease differ distinctly from the profiles of clinically related connective tissue diseases. Rheumatology 54(3):528–535

  23. Lage LV, Caleiro MT, Carvalho JF (2010) Proposed disease activity criteria for mixed connective tissue disease. Lupus 19(2):223–224. https://doi.org/10.1177/0961203309345782

    Article  CAS  PubMed  Google Scholar 

  24. Rayes HA, Al-Sheikh A, Al Dalaan A, Al Saleh S (2002) Mixed connective tissue disease: the King Faisal Specialist Hospital experience. Ann Saudi Med 22(1–2):43–46

  25. Habets WJ, de Rooij DJ, Salden MH, Verhagen AP, van Eekelen CA, van de Putte LB, van Venrooij WJ (1983) Antibodies against distinct nuclear matrix proteins are characteristic for mixed connective tissue disease. Clin Exp Immunol 54(1):265–276

    CAS  PubMed  PubMed Central  Google Scholar 

  26. Xuan Z, Yi D, Fu-Lin T, Fen-Chun Z (1999) Central nervous system involvement in systemic lupus erythematosus in a hospital-based study of 171 cases: the possible therapeutic role of intrathecal therapy. J Clin Rheumatol 5(6):314–319

  27. Bennett RM, Bong DM, Spargo BH (1978) Neuropsychiatric problems in mixed connective tissue disease. Am J Med 65(6):955–962

    Article  CAS  PubMed  Google Scholar 

  28. Burdt MA, Hoffman RW, Deutscher SL, Wang GS, Johnson JC, Sharp GC (1999) Long-term outcome in mixed connective tissue disease: longitudinal clinical and serologic findings. Arthritis Rheum 42(5):899–909. https://doi.org/10.1002/1529-0131(199905)42:5<899::aid-anr8>3.0.co;2-l

    Article  CAS  PubMed  Google Scholar 

  29. Hojaili B, Barland P (2006) Trigeminal neuralgia as the first manifestation of mixed connective tissue disorder. J Clin Rheumatol 12(3):145–147. https://doi.org/10.1097/01.rhu.0000222045.70861.a5

  30. Debette S, Germain DP (2014) Neurologic manifestations of inherited disorders of connective tissue. Handb Clin Neurol 119:565–576. https://doi.org/10.1016/b978-0-7020-4086-3.00037-0

    Article  PubMed  Google Scholar 

  31. Nadeau SE (2002) Neurologic manifestations of connective tissue disease. Neurol Clin 20(1):151–178 vi

    Article  PubMed  Google Scholar 

  32. Karmacharya P, Mainali N, Aryal M, Lloyd B (2013) Recurrent case of ibuprofen-induced aseptic meningitis in mixed connective tissue disease. BMJ Case Rep 2013. https://doi.org/10.1136/bcr-2013-009571

  33. Sato T, Fujii T, Yokoyama T, Fujita Y, Imura Y, Yukawa N, Kawabata D, Nojima T, Ohmura K, Usui T, Mimori T (2010) Anti-U1 RNP antibodies in cerebrospinal fluid are associated with central neuropsychiatric manifestations in systemic lupus erythematosus and mixed connective tissue disease. Arthritis Rheum 62(12):3730–3740. https://doi.org/10.1002/art.27700

  34. Shah P, Dhakre V, Bhabhor A, Prasad A (2018) Superior sagittal sinus thrombosis in a case of mixed connective tissue disease. BMJ Case Rep 2018. https://doi.org/10.1136/bcr-2018-225078

  35. Kim ST, Brinjikji W, Lanzino G, Kallmes DF (2016) Neurovascular manifestations of connective-tissue diseases: a review. Interv Neuroradiol 22(6):624–637. https://doi.org/10.1177/1591019916659262

  36. Matsui H, Udaka F, Oda M, Kubori T, Nishinaka K, Kameyama M (2006) Encephalopathy and severe neuropathy due to probable systemic vasculitis as an initial manifestation of mixed connective tissue disease. Neurol India 54(1):83–85

  37. Leibfarth J, Persellin R (1976) Characteristics of patients with serum antibodies to extractable nuclear antigens. Arthritis Rheum 19(5):851–856

    Article  CAS  PubMed  Google Scholar 

  38. Hajas A, Szodoray P, Barath S, Sipka S, Rezes S, Zeher M, Sziklai I, Szegedi G, Bodolay E (2009) Sensorineural hearing loss in patients with mixed connective tissue disease: immunological markers and cytokine levels. J Rheumatol 36(9):1930–1936

    Article  CAS  PubMed  Google Scholar 

  39. Kiani I, Qureshi S, Shah F (2014) Depression and seizures as the main neuropsychiatric manifestation of mixed connective tissue disorder. J Coll Physicians Surg Pak 24(Suppl 2):S141–S143

    PubMed  Google Scholar 

  40. Manohar H, Kuppili P, Menon V (2017) Major depression: An under reported neuropsychiatric manifestation of mixed connective tissue disease. Asian J Psychiatr 30:54–55

  41. Nowicka-Sauer K, Czuszynska Z, Majkowicz M, Smolenska Z, Jarmoszewicz K, Olesinska M, Siebert J (2012) Neuropsychological assessment in mixed connective tissue disease: comparison with systemic lupus erythematosus. Lupus 21(9):927–933

    Article  CAS  PubMed  Google Scholar 

  42. Laffon-Pioger M, Rocher F, Cohen M, Chanalet S, Thomas P, Lebrun C (2010) Bilateral optic neuropathy with loss of vision after an influenza vaccination in a patient suffering from mixed connective tissue disease. Rev Neurol (Paris) 166(12):1024–1027

    Article  CAS  Google Scholar 

  43. Flechtner K, Baum K (1994) Mixed connective tissue disease: recurrent episodes of optic neuropathy and transverse myelopathy. Successful treatment with plasmapheresis. J Neurol Sci 126(2):146–148

    Article  CAS  PubMed  Google Scholar 

  44. Pedersen C, Bonen H, Boesen F (1987) Transverse myelitis in mixed connective tissue disease. Clin Rheumatol 6(2):290–292

    Article  CAS  PubMed  Google Scholar 

  45. Obara K, Tanaka K (1991) A case of mixed connective tissue disease (MCTD) associated with transverse myelitis responding to pulse therapy. Rinsho Shinkeigaku 31(11):1197–1201

  46. Mok CC, Lau CS (1995) Transverse myelopathy complicating mixed connective tissue disease. Clin Neurol Neurosurg 97(3):259–260

    Article  CAS  PubMed  Google Scholar 

  47. Bhinder S, Harbour K, Majithia V (2007) Transverse myelitis, a rare neurological manifestation of mixed connective tissue disease--a case report and a review of literature. Clin Rheumatol 26(3):445–447. https://doi.org/10.1007/s10067-005-0158-1

    Article  PubMed  Google Scholar 

  48. Hao Y, Feng L, Teng Y, Cheng Y, Feng J (2018) Management of multiple neurological complications in mixed connective tissue disease: a case report. Medicine 97(31):e11360. https://doi.org/10.1097/md.0000000000011360

    Article  PubMed  PubMed Central  Google Scholar 

  49. Weatherby SJ, Davies MB, Hawkins CP, Haq N, Dawes P (2000) Transverse myelopathy, a rare complication of mixed connective tissue disease: comparison with SLE related transverse myelopathy. J Neurol Neurosurg Psychiatry 68(4):532–533

    Article  PubMed  PubMed Central  Google Scholar 

  50. Kucuk A, Uslu AU, Yilmaz R, Salbas E, Solak Y, Tunc R (2017) Relationship between prevalence and severity of restless legs syndrome and anemia in patients with systemic lupus erythematosus. Int J Rheum Dis 20(4):469–473. https://doi.org/10.1111/1756-185x.12793

    Article  CAS  PubMed  Google Scholar 

  51. Schedel J, Kuchenbuch S, Schoelmerich J, Feuerbach S, Geissler A, Mueller-Ladner U (2010) Cerebral lesions in patients with connective tissue diseases and systemic vasculitides: are there specific patterns? Ann N Y Acad Sci 1193:167–175

    Article  PubMed  Google Scholar 

  52. Hetlevik S, Flatø B, Rygg M, Nordal E, Brunborg C, Hetland H, Lilleby V (2017) Long-term outcome in juvenile-onset mixed connective tissue disease: a nationwide Norwegian study. Ann Rheum Dis 76(1):159–165

    Article  PubMed  Google Scholar 

  53. Rahmanzadeh R, Rahmanzade R, Zabihiyeganeh M (2016) Posterior reversible encephalopathy syndrome in a patient with mixed connective tissue disease: a case report. J Med Case Rep 10(1):145

    Article  PubMed  PubMed Central  Google Scholar 

  54. Tristano A (2009) Autoimmune diseases associated with transverse myelitis. Review. Investig Clin 50(2):251–270

    Google Scholar 

  55. Nived O, Sturfelt G, Liang MH, De Pablo P (2003) The ACR nomenclature for CNS lupus revisited. Lupus 12(12):872–876. https://doi.org/10.1191/0961203303lu495oa

    Article  CAS  PubMed  Google Scholar 

  56. Kovacs B, Lafferty TL, Brent LH, DeHoratius RJ (2000) Transverse myelopathy in systemic lupus erythematosus: an analysis of 14 cases and review of the literature. Ann Rheum Dis 59(2):120–124

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  57. Ahn S, Hong S, Lim D, Ghang B, Kim Y, Lee C, Yoo B (2018) Clinical features and prognoses of acute transverse myelitis in patients with systemic lupus erythematosus. Korean J Intern Med. 34(2):442-451. doi: 10.3904/kjim.2016.383. 

  58. Chiganer E, Hryb J, Carnero Contentti E (2017) Myelitis and lupus: clinical manifestations, diagnosis and treatment. Review Reumatol Clin 13(6):344–348

    Article  PubMed  Google Scholar 

  59. Zahid A, Mubashir A, Mirza S, Naqvi I, Talib A (2018) Systemic lupus erythematosus presenting as longitudinally extensive transverse myelitis and nephritis: a case report. Cureus 10(4):e2402

    PubMed  PubMed Central  Google Scholar 

  60. Saison J, Costedoat-Chalumeau N, Maucort-Boulch D, Iwaz J, Marignier R, Cacoub P, Vital-Durand D, Hot A, Tebib J, Aumaitre O, Schleinitz N, Sarrot-Reynauld F, Broussolle C, Seve P (2015) Systemic lupus erythematosus-associated acute transverse myelitis: manifestations, treatments, outcomes, and prognostic factors in 20 patients. Lupus 24(1):74–81. https://doi.org/10.1177/0961203314547795

  61. Harel L, Sandborg C, Lee T, von Scheven E (2006) Neuropsychiatric manifestations in pediatric systemic lupus erythematosus and association with antiphospholipid antibodies. J Rheumatol 33(9):1873–1877

  62. Proposed diagnostic criteria and nosology of acute transverse myelitis (2002). Neurology 59 (4):499–505

  63. Flores-Silva F, Longoria-Lozano O, Aguirre-Villarreal D, Sentíes-Madrid H, Vega-Boada F, Díaz de León-Sánchez E, Murra-Antón S, Morales-Moreno S, Quintanilla-González L, Fragoso-Loyo H, Guraieb-Chaín P, Higuera-Calleja J, Ceballos-Ceballos J, Treviño-Frenk I, González-Duarte A, Dávila-Maldonado L, Cantú-Brito C, Valdés-Ferrer S (2018) Natural history of longitudinally extensive transverse myelitis in 35 Hispanic patients with systemic lupus erythematosus: good short-term functional outcome and paradoxical increase in long-term mortality. Lupus 27(8):1279–1286

    Article  CAS  PubMed  Google Scholar 

  64. Chan K, Boey M (1996) Transverse myelopathy in SLE: clinical features and functional outcomes. Lupus 5(4):294–299

    Article  CAS  PubMed  Google Scholar 

  65. Lehnhardt F, Scheid C, Holtik U, Burghaus L, Neveling M, Impekoven P, Rüger A, Hallek M, Jacobs A, Rubbert A (2006) Autologous blood stem cell transplantation in refractory systemic lupus erythematodes with recurrent longitudinal myelitis and cerebral infarction. Lupus 15(4):240–243

    Article  CAS  PubMed  Google Scholar 

  66. Sherer Y, Hassin S, Shoenfeld Y, Levy Y, Livneh A, Ohry A, Langevitz P (2002) Transverse myelitis in patients with antiphospholipid antibodies--the importance of early diagnosis and treatment. Clin Rheumatol 21(3):207–210

    Article  CAS  PubMed  Google Scholar 

  67. Soltesz P, Bereczki D, Szodoray P, Magyar M, Der H, Csipo I, Hajas A, Paragh G, Szegedi G, Bodolay E (2010) Endothelial cell markers reflecting endothelial cell dysfunction in patients with mixed connective tissue disease. Arthritis Res Ther 12(3):R78

  68. Haładyj E, Paradowska-Gorycka A, Felis-Giemza A, Olesińska M (2016) Immunity and early atherosclerosis in the course of systemic lupus erythematosus, mixed connective tissue disease and antiphospholipid syndrome. Reumatologia 54(4):187–195

    Article  PubMed  PubMed Central  Google Scholar 

  69. Hajas A, Sandor J, Csathy L, Csipo I, Barath S, Paragh G, Seres I, Szegedi G, Shoenfeld Y, Bodolay E (2011) Vitamin D insufficiency in a large MCTD population. Autoimmun Rev 10(6):317–324

    Article  CAS  PubMed  Google Scholar 

  70. Svenungsson E, Cederholm A, Jensen-Urstad K, Fei G, de Faire U, Frostegård J (2008) Endothelial function and markers of endothelial activation in relation to cardiovascular disease in systemic lupus erythematosus. Scand J Rheumatol 37(5):352–359

    Article  CAS  PubMed  Google Scholar 

  71. Bakri Hassan A, Rönnelid J, Gunnarsson I, Karlsson G, Berg L, Lundberg I (1998) Increased serum levels of immunoglobulins, C-reactive protein, type 1 and type 2 cytokines in patients with mixed connective tissue disease. J Autoimmun 11(5):503–508

    Article  CAS  PubMed  Google Scholar 

  72. Bodolay E, Prohászka Z, Paragh G, Csipő I, Nagy G, Laczik R, Demeter N, Zöld E, Nakken B, Szegedi G, Szodoray P (2014) Increased levels of anti-heat-shock protein 60 (anti-Hsp60) indicate endothelial dysfunction, atherosclerosis and cardiovascular diseases in patients with mixed connective tissue disease. Immunol Res 60(1):50–59

    Article  CAS  PubMed  Google Scholar 

  73. Tristano AG (2009) Autoimmune diseases associated with transverse myelitis. Rev Investig Clin 50(2):251–270

    Google Scholar 

  74. Habek M, Adamec I, Pavliša G, Brinar V (2012) Diagnostic approach of patients with longitudinally extensive transverse myelitis. Acta Neurol Belg 112(1):39–43

    Article  PubMed  Google Scholar 

  75. Kayal A, Goswami M, Das M, Basumatary L, Bhowmick S, Synmon B (2017) Etiological profile of noncompressive myelopathies in a tertiary care hospital of Northeast India. Ann Indian Acad Neurol 20(1):41–50

    Article  PubMed  PubMed Central  Google Scholar 

  76. Wang F, Guo D, Liu Z, Zhou A, Wei C, Jia J (2018) Neurosarcoidosis: clinical characteristics, diagnosis, and treatment in eight Chinese patients. Neurol Sci 39(10):1725–1733. https://doi.org/10.1007/s10072-018-3491-2

    Article  CAS  PubMed  Google Scholar 

  77. Novy J, Carruzzo A, Maeder P, Bogousslavsky J (2006) Spinal cord ischemia: clinical and imaging patterns, pathogenesis, and outcomes in 27 patients. Arch Neurol 63(8):1113–1120

    Article  PubMed  Google Scholar 

  78. Masson C, Pruvo J, Meder J, Cordonnier C, Touzé E, De La Sayette V, Giroud M, Mas J, Leys D (2004) Spinal cord infarction: clinical and magnetic resonance imaging findings and short term outcome. J Neurol Neurosurg Psychiatry 75(10):1431–1435

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  79. Vaknin-Dembinsky A, Karussis D, Avichzer J, Abramsky O (2014) NMO spectrum of disorders: a paradigm for astrocyte-targeting autoimmunity and its implications for MS and other CNS inflammatory diseases. J Autoimmun 54:93–99

    Article  CAS  PubMed  Google Scholar 

  80. NL Z, PP M, BG W, CF L, Y G SJP, KN K, TJ K, DM W, N K EPF (2017) Ring-enhancing spinal cord lesions in neuromyelitis optica spectrum disorders. J Neurol Neurosurg Psychiatry 88(3):218–225

    Article  Google Scholar 

  81. Ogaki K, Hirayama T, Chijiiwa K, Fukae J, Furuya T, Noda K, Fujishima K, Hattori N, Takahashi T, Okuma Y (2012) Anti-aquaporin-4 antibody-positive definite neuromyelitis optica in a patient with thymectomy for myasthenia gravis. Neurologist 18(2):76–79

    Article  PubMed  Google Scholar 

  82. Metz L, Li D, Traboulsee A, Duquette P, Eliasziw M, Cerchiaro G, Greenfield J, Riddehough A, Yeung M, Kremenchutzky M, Vorobeychik G, Freedman M, Bhan V, Blevins G, Marriott J, Grand'Maison F, Lee L, Thibault M, Hill M, Yong V (2017) Trial of minocycline in a clinically isolated syndrome of multiple sclerosis. N Engl J Med 376(22):2122–2133

    Article  CAS  PubMed  Google Scholar 

  83. Dehghani A, Nayeri N, Ebadi A (2017) Development and validation of the coping with multiple sclerosis questionnaire. Mult Scler Relat Disord 18:49–55

    Article  PubMed  Google Scholar 

  84. Axisa P, Hafler D (2016) Multiple sclerosis: genetics, biomarkers, treatments. Curr Opin Neurol 29(3):345–353

    Article  CAS  PubMed  Google Scholar 

  85. Kitzler H, Wahl H, Eisele J, Kuhn M, Schmitz-Peiffer H, Kern S, Rutt B, Deoni S, Ziemssen T, Linn J (2018) Multi-component relaxation in clinically isolated syndrome: lesion myelination may predict multiple sclerosis conversion. Neuroimage Clin 20:61–70

    Article  PubMed  PubMed Central  Google Scholar 

  86. Jacob A, McKeon A, Nakashima I, Sato D, Elsone L, Fujihara K, de Seze J (2013) Current concept of neuromyelitis optica (NMO) and NMO spectrum disorders. J Neurol Neurosurg Psychiatry 84(8):922–930

    Article  PubMed  Google Scholar 

  87. Zhou C, He Y, Gao X, Zhu Y, Chao Z, Wang X (2018) Neuromyelitis optical spectrum disorders presenting with isolated “inverted V” sign in area postrema. Neurol Sci 39(7):1299–1301. https://doi.org/10.1007/s10072-018-3302-9

    Article  PubMed  Google Scholar 

  88. EP F, BG W, KN K, VA L, CF L, A M DMW, EA S, Y J ESH, SJ P (2015) Short myelitis lesions in aquaporin-4-IgG-positive neuromyelitis optica spectrum disorders. JAMA neurology 72(1):81–87

    Article  Google Scholar 

  89. Zhong YH, Zhong ZG, Zhou Z, Ma ZY, Qiu MY, Peng FH, Zhang WX (2017) Comparisons of presentations and outcomes of neuromyelitis optica patients with and without Sjogren's syndrome. Neurol Sci 38(2):271–277. https://doi.org/10.1007/s10072-016-2751-2

    Article  PubMed  Google Scholar 

  90. Squatrito D, Colagrande S, Emmi L (2010) Devic's syndrome and primary APS: a new immunological overlap. Lupus 19(11):1337–1339

    Article  CAS  PubMed  Google Scholar 

  91. Mehta L, Samuelsson M, Kleiner A, Goodman A, Anolik J, Looney R, Schwid S (2008) Neuromyelitis optica spectrum disorder in a patient with systemic lupus erythematosus and anti-phospholipid antibody syndrome. Mult Scler 14(3):425–427

    Article  PubMed  Google Scholar 

  92. Kister I, Gulati S, Boz C, Bergamaschi R, Piccolo G, Piccolo G, Oger J, Swerdlow M (2006) Neuromyelitis optica in patients with myasthenia gravis who underwent thymectomy. Arch Neurol 63(6):851–856

    Article  PubMed  Google Scholar 

  93. Arabshahi B (2006) Devic disease in a child with primary Sjogren syndrome. J Child Neurol 21(4):284–286

    Article  PubMed  Google Scholar 

  94. RN S (2018) Metabolic and toxic myelopathies. Continuum (Minneapolis, Minn) 24(2):427–440

  95. AH K, A M GB (2000) Subacute combined degeneration of the spinal cord with involvement of the anterior columns: a new MRI finding. Neuroradiology 42(2):115–117

    Article  Google Scholar 

  96. N K JEA, CJ K, JD P (2006) Imaging features of copper deficiency myelopathy: a study of 25 cases. Neuroradiology 48(2):78–83

    Article  Google Scholar 

  97. Armstrong D, McCarron M, Wright G (2006) SLE-associated transverse myelitis successfully treated with Rituximab (anti-CD20 monoclonal antibody). Rheumatol Int 26(8):771–772

    Article  CAS  PubMed  Google Scholar 

  98. Klaiman MD, Miller SD (1993) Transverse myelitis complicating systemic lupus erythematosus: treatment including hydroxychloroquine. Case report. Am J Phys Med Rehabil 72(3):158–161

    Article  CAS  PubMed  Google Scholar 

Download references

Acknowledgments

The authors thank Dr. Mingqin Zhu for her guidance and support to this paper.

Author information

Authors and Affiliations

  1. Department of Neurology and Neuroscience center, First Hospital of Jilin University, 72 Xinming Street, Chaoyang District, Changchun, 130021, Jilin Province, People’s Republic of China

    Yulei Hao, Meiying Xin, Shuang Wang, Di Ma & Jiachun Feng

Authors
  1. Yulei Hao
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Meiying Xin
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Shuang Wang
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Di Ma
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Jiachun Feng
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Jiachun Feng.

Ethics declarations

Conflict of interest

The authors declare that they have no conflict of interest.

Additional information

Publisher’s note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Hao, Y., Xin, M., Wang, S. et al. Myelopathy associated with mixed connective tissue disease: clinical manifestation, diagnosis, treatment, and prognosis. Neurol Sci 40, 1785–1797 (2019). https://doi.org/10.1007/s10072-019-03935-y

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s10072-019-03935-y

Keywords

Search

Navigation